By proceeding with your purchase, you confirm that you have read, understood, and agreed to these terms
Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer
NMPAs goals for the document include ensuring marketing authorization holders (MAHs) and contract manufacturers jointly ensure drug quality and safety, and clarifying the obligations and responsibilities of all parties
doi: 10.1038/s41416-022-01747-0 120 TianSPengPLiJDengHZhanNZengZet al
Tsuji, N., Nishikori, S., Iwabe, O., Shiraki, K., Miyasaka, H., Takagi, M., Hirata, K., & Miyamoto, K
Think of it as support from the inside that complements your existing routine rather than replacing topical care, professional facials, or any procedures you may choose to pursue separately